J B Chemicals & Pharmaceuticals Ltd Q1 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/g7ttkl84ge6a3ynk6vjou6q0.pdf

Key Takeaways


Domestic Business & Brand Performance

Kunal Khanna: "The sharp price, which you saw with the price reduction itself is a reflection of what the market opportunity is really. And whatever change you have seen over the past 5 months to 6 months has not happened because systemically the market has changed."

International Business & CDMO

Nikhil Chopra: "We are in a very sweet spot in terms of what we have got very good partners, and the relationship has been here for the last now 2 decades plus."

Margins & Efficiency

Nikhil Chopra: "We'll be more than happy to be on the higher side of the range. But all the three aspects have worked for us in terms of top line and in terms of mix, in terms of efficiency, that is where we stand as a company. So our guidance continues to be between 25% to 27% of EBITDA margin."

Portfolio & M&A Strategy

Nikhil Chopra: "There is no pressure on us to do any M&A just for the sake of doing an acquisition."

API & Other Segments


Guidance & Commitments

CommitmentSpecificsTimeline
India business growthBeat IPM by 300-400 bpsNext three quarters
International business growthDouble-digit growthOngoing
EBITDA margin25-27% range, bias to higher sideOngoing
Gross margin65-66% rangeOngoing
Chronic contributionReach 60% of domestic businessNo date (in progress)
Razel growthAt least double-digit vs flat prior 3-year CAGROngoing
API recoveryCover major part of Q1 muted trendH2 FY24
US ANDA filingsMaintain run rate of 2-3 filings per yearOngoing
US approvalsEnsure approvals come through on 4 filings from last yearNext 12-14 months
Lozenges packaging capacityReach 18-20 crore from current 14 croreNext 12 months
Cash flowBecome cash positiveFY23-24
M&A payback thresholdClose to six years; appetite up to 1.5% of EBITDA absoluteOngoing discipline

Key Metrics

MetricQ1 FY24
Revenue₹896 cr, +14% YoY
Domestic revenue₹489 cr, +17% YoY
International revenue₹407 cr, +11% YoY
International formulations revenue₹275 cr, +12% YoY
CDMO revenue~₹120 cr, +19% YoY
Gross margin65.4%, +270 bps YoY
Operating EBITDA (ex-ESOP)₹243 cr, +28% YoY
Operating EBITDA margin (ex-ESOP)27.1%, +290 bps YoY
Profit after tax₹142 cr, +35% YoY
Employee cost as % of sales16.6%, improved from 17.1% YoY
Other expenses as % of salesimproved by ~100 bps YoY
IQVIA MAT growth (J.B. vs IPM)20.7% vs 10.6%
Chronic portfolio contribution (domestic)54–55%, up from ~53% last year
Razel monthly sales (June 2023)₹6.7 cr, up from ₹5.5 cr monthly avg in FY22
Azmarda market share16–18%
Sporlac portfolio revenue~₹90 cr, acquired at ₹60–65 cr
Rantac monthly run rate₹15–16 cr, volumes 45–50 lakh units
API business sales-40% YoY
Lozenges capacity utilization (manufacturing)~11 cr lozenges out of 18 cr capacity
EBITDA margin guidance (FY24)25–27%
Domestic growth guidancebeat IPM by 300–400 bps